Surial B, Mugglin C, Calmy A, Cavassini M, Günthard HF, Stöckle M, Bernasconi E, Schmid P, Tarr PE, Furrer H, Ledergerber B, Wandeler G, Rauch A; Swiss HIV Cohort Study. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. Ann Intern Med.
Month: June 2021
Mycobacterium abscessus therapy is kind of a crapshoot. It is unfortunate to say it like that yet the resistance profiles for this complex of mycobacteria and the microbiology of it make it a frustrating organism to treat. This organism has been called an “antibiotic nightmare” for multiple reasons. Let’s start here. M. abscessus (as I
Consider this post a continuation of the prior one on prophylaxis. I mention a bit on the pathophysiology, where adaptive immunity seems to play a key role in the way the body deals with the fungus, with mice with SCID infected with pneumocystis not being able to mount an inflammatory response. As a result of
First identified by Carlos Chagas (yes, that Chagas) back in 1909, pneumocystis was identified as a cause of plasma cell pneumonia in debilitated infants following WWII (1). Since then, it has been identified as a unicellular fungus that is of low virulence and unique amongst the other fungi in that it lacks ergosterol in its
Some isavuconazole news, a PJI trial, a few HIV-related articles, and therapies for COVID that won’t die. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA,
Dr. Germophile 